Comparison of Preterm Delivery Rates between HIV-Infected Pregnant Women Receiving Highly Active Antiretroviral Therapy (HAART) Containing Protease Inhibitors (PIs) and HIV-infected Pregnant Women Receiving Zidovudine Monotherapy

Abstract

Objective: To compare the preterm delivery rates between pregnant women receiving HAART containing protease inhibitors (HAART-PIs) and zidovudine monotherapy (ZDVm) during pregnancy.

Materials and Methods: A retrospective study was conducted in antiretroviral-naïve HIV-infected pregnant women who received antiretroviral drugs during pregnancy at least 4 weeks and delivered in Maharaj Nakorn Chiang Mai Hospital, Chiang Mai, Thailand between January 2002 and December 2013. Preterm delivery rates were compared between HAART-PIs and ZDVm groups.

Results: Of the 166 pregnant women who received antiretroviral drugs, 24 (14.5%) pregnant women delivered before 37 completed weeks. The incidence of preterm delivery was higher in the HAART-PIs group (82 cases) than in the ZDVm group (84 cases), but the difference was not significant (18.3% vs. 10.7%, p = 0.17).

Conclusion: The almost twofold incidence of preterm delivery rate was observed in those pregnancy women who received HAART-PIs; however, it was not significantly different from the rate among those who received ZDVm.